Cypress Bioscience (CYPB) Reports Q1 Loss of $0.24
More News related to CYPB
- Cypress Bioscience, Inc. to Present at the Piper Jaffray 21st Annual Health Care Conference
- Trading Outlook for Hard To Treat Diseases Inc. Issued by InvestorSoup.com
- Cypress Bioscience Announces Third Quarter 2009 Financial Results
- Oppenheimer Upgrades Cypress Bioscience (CYPB) to Outperform
- Cypress Bioscience, Inc. to Present at Oppenheimer 20th Annual Healthcare Conference
More News related to Earnings
- China BAK (CBAK) Shares Tumble Amid Q4 Results, Roth Capital Downgrade
- Canaccord Adams Downgrades Micromet (MITI) to Hold
- Credit Suisse Downgrades Pepco Holdings (POM) to Neutral
- Wells Fargo Downgrades Boardwalk Pipeline Partners, L.P. (BWP) to Market Perform; Valuation Call
- Airline Stocks Rising Again as Morgan Stanley Upgrades Sector to 'Attractive' (AMR, UAUA, ALK, ALGT)
Cypress Bioscience, Inc. (NASDAQ: CYPB) reports Q1 loss of $0.24, versus the analyst estimate of $0.12 and compared to a loss of $0.08 in the same period last year. Revenue for the quarter was $7.9 million, versus the consensus of $14.61 million.
Related Categories
EarningsStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
